Bai Ruoli, Covell David G, Liu Chunfeng, Ghosh Arun K, Hamel Ernest
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA.
J Biol Chem. 2002 Aug 30;277(35):32165-71. doi: 10.1074/jbc.M205076200. Epub 2002 Jun 20.
The cytotoxic, cyclic depsipeptide (-)-doliculide was originally isolated by Ishiwata et al. (Ishiwata, H., Nemoto, T., Ojika, M., and Yamada, K. (1994) J. Org. Chem. 59, 4710-4711 and Ishiwata, H., Sone, H., Kigoshi, H., and Yamada, K. (1994) J. Org. Chem. 59, 4712-4713) from the sea hare Dolabella auricularia collected in Japanese waters, but the mechanism of action of the depsipeptide was not known. Using synthetic (-)-doliculide, we found that the compound arrests cells at the G(2)/M phase of the cell cycle by interfering with normal actin assembly. In cells, normal stress fibers disappeared and were replaced by multiple clumps of apparently aggregated F-actin. These effects of (-)-doliculide on cells were essentially identical to those obtained with jasplakinolide. Like jasplakinolide, (-)-doliculide caused the hyperassembly of purified actin into F-actin as measured both fluorometrically and by centrifugation. In addition, (-)-doliculide, like jasplakinolide, readily displaced a fluorescent phalloidin derivative from actin polymer. In these biochemical assays (-)-doliculide and jasplakinolide were quantitatively virtually identical in their behaviors. Similar effects have also been reported with a series of depsipeptides known as chondramides. Using recently developed, computer-driven shape descriptor analysis (Mansfield, M. L., Covell, D. G., and Jernigan, R. L. (2002) J. Chem. Inf. Comput. Sci. 42, 259-273), we compared (-)-doliculide with jasplakinolide, phalloidin, and chondramide C to gain insight into a possible pharmacophore that would explain the apparent binding of this diverse group of molecules at the same site on F-actin. We found that the segment of (-)-doliculide that best overlapped the other molecules encompassed its phenyl and isopropyl side chains and the portion of the macrocycle between these substituents.
细胞毒性环缩肽(-)-多利库利德最初是由石渡等人(石渡浩、根本敏夫、尾木佳史和山田康夫,(1994年)《有机化学杂志》59卷,4710 - 4711页;石渡浩、曾根秀树、木越浩和山田康夫,(1994年)《有机化学杂志》59卷,4712 - 4713页)从采集于日本海域的海兔多鳃孔舌形贝中分离得到的,但该环缩肽的作用机制尚不清楚。我们使用合成的(-)-多利库利德发现,该化合物通过干扰正常的肌动蛋白组装,使细胞停滞在细胞周期的G2/M期。在细胞中,正常的应力纤维消失,取而代之的是多团明显聚集的F - 肌动蛋白。(-)-多利库利德对细胞的这些作用与茉莉素内酯所产生的作用基本相同。与茉莉素内酯一样,(-)-多利库利德能使纯化的肌动蛋白超组装成F - 肌动蛋白,这一过程通过荧光测定法和离心法均可检测到。此外,(-)-多利库利德与茉莉素内酯一样,能轻易地将一种荧光鬼笔环肽衍生物从肌动蛋白聚合物上置换下来。在这些生化分析中,(-)-多利库利德和茉莉素内酯在行为上在数量上几乎是相同的。一系列被称为软骨酰胺的环缩肽也有类似的作用报道。我们使用最近开发的计算机驱动的形状描述符分析(曼斯菲尔德,M. L.、科维尔,D. G.和杰尔尼根,R. L.,(2002年)《化学信息与计算机科学杂志》42卷,259 - 273页),将(-)-多利库利德与茉莉素内酯、鬼笔环肽和软骨酰胺C进行比较,以深入了解一种可能的药效基团,该药效基团可以解释这一类不同分子在F - 肌动蛋白上的同一位点的明显结合。我们发现,(-)-多利库利德中与其他分子重叠最好的部分包括其苯基和异丙基侧链以及这些取代基之间大环的部分。